Pregnancy and the risk of breast cancer

被引:160
作者
Britt, Kara [1 ,2 ]
Ashworth, Alan [1 ]
Smalley, Matthew [1 ]
机构
[1] Breakthrough Breast Canc Res Ctr, Inst Canc Res, London SW3 6JB, England
[2] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
关键词
ESTROGEN-RECEPTOR-ALPHA; MOUSE MAMMARY-GLAND; GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; BRCA2 MUTATION CARRIERS; PLASMA PROLACTIN LEVELS; MESSENGER-RNA VARIANTS; ATOMIC-BOMB SURVIVORS; SHORT-TERM EXPOSURE; PROGESTERONE-RECEPTOR;
D O I
10.1677/ERC-07-0137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is well established that childless women and women having children later in life are at an increased risk of developing breast cancer. In particular, women having a first child before 20 years of age have a 50% reduction in lifetime breast cancer risk when compared with women who do not have children. This protective effect is specific for estrogen receptor positive breast cancer. Nevertheless, it remains unclear how parity decreases breast cancer risk. Possible mechanisms of action include changes to the hormonal profile of parous women, a more differentiated and so less susceptible mammary gland or changes within specific epithelial cell subpopulations. In this review, we discuss the epidemiological evidence for the protective effects of parity on breast cancer. We also explore the mechanisms by which parity protects, with a particular emphasis on the role of stem cells and the interactions between stem cells and estrogen.
引用
收藏
页码:907 / 933
页数:27
相关论文
共 277 条
  • [1] ABE O, 1992, LANCET, V339, P71
  • [2] Abrams TJ, 1998, ANTICANCER RES, V18, P4115
  • [3] Adeyemo O, 1993, Afr J Med Med Sci, V22, P55
  • [4] Aisenberg AC, 1997, CANCER, V79, P1203, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO
  • [5] 2-2
  • [6] Breast cancer risk by age at birth, time since birth and time intervals between births:: exploring interaction effects
    Albrektsen, G
    Heuch, I
    Hansen, S
    Kvåle, G
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 167 - 175
  • [7] Anbazhagan R, 1998, J PATHOL, V184, P197, DOI 10.1002/(SICI)1096-9896(199802)184:2<197::AID-PATH992>3.0.CO
  • [8] 2-J
  • [9] [Anonymous], 1992, Lancet, V339, P1
  • [10] Ansquer Y, 2005, ANTICANCER RES, V25, P4535